Skip to main content

Advertisement

SpringerLink
Log in

When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy?

  • Breast Cancer (B Overmoyer, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Postmastectomy radiation therapy (PMRT) has been shown to reduce the risk of locoregional recurrences (LRR) and of distant metastases (DM) and to improve breast cancer–specific survival (BCSS) as well as overall survival (OS) in patients with locally advanced breast cancer who are considered high risk because of large tumors (> 5 cm) and/or presence of axillary lymph node involvement.

Recent Findings

Controversy is still ongoing with respect to the indication of PMRT in the case of earlier stage invasive tumors in the presence of risk factors including young age, premenopausal status, presence of lymphovascular invasion (LVI), high tumor grade, or tumor size 2–5 cm. Simultaneously, the evolution of our understanding of breast cancer biology has led us to better identify patients for whom the administration of systemic treatment prior to surgery reduces tumor load, not only in the case of locally advanced tumors but also for earlier stages, namely in the case of unfavorable molecular subtypes. The role of PMRT in the context of these patients treated with primary systemic therapy (PST), especially after a good tumor response, is under evaluation by various studies.

Summary

This review identifies factors that may permit PMRT omission in a selected group of patients after PST.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97(2):116–26.

    Article  PubMed  Google Scholar 

  2. Overgaard M, Hansen PS, Overgaard J, Carsten R, Andersson M, Bah F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337:949–55.

    Article  CAS  PubMed  Google Scholar 

  3. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8.

    Article  CAS  PubMed  Google Scholar 

  4. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82(3):247–53.

    Article  PubMed  Google Scholar 

  5. Li Y, Moran MS, Huo Q, Yang Q, Haffty BG. Post-mastectomy radiotherapy for breast cancer patients with T1-T2 and 1-3 positive lymph nodes: a meta-analysis. PLoS One. 2013;8(12):1–9.

    Article  Google Scholar 

  6. Poortmans P. Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. Lancet. 2014;383(9935):2104–6.

    Article  PubMed  Google Scholar 

  7. Johnson ME, Handorf EA, Martin JM, Hayes SB. Postmastectomy radiation therapy for T3N0: a SEER analysis. Cancer. 2014;120(22):3569–74.

    Article  PubMed  Google Scholar 

  8. • Francis SR, Frandsen J, Kokeny KE, Gaffney DK, Poppe MM. Outcomes and utilization of postmastectomy radiotherapy for T3N0 breast cancers. Breast. 2017;32:156–61 A review based upon NCDB data focused on the use of PMRT in large and negative lymph nodes breast tumors (T3N0) suggesting survival advantage.

    Article  PubMed  Google Scholar 

  9. • Cassidy RJ, Liu Y, Kahn ST, Jegadeesh NK, Liu X, Subhedar PD, et al. The role of postmastectomy radiotherapy in women with pathologic T3N0M0 breast cancer. Cancer. 2017;54(PROC):1–2 Based upon data from NCDB (National Cancer Database), this review confirms benefit in overall survival with PMRT in pT3N0 tumors.

    Google Scholar 

  10. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007 Oct;94(10):1189–200.

    Article  CAS  Google Scholar 

  11. Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes. JAMA Oncol. 2016;2(6):751–60.

    Article  PubMed  Google Scholar 

  12. Li J, et al. Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy. Oncotarget. 2017;8(11):18399–408.

    Article  PubMed  Google Scholar 

  13. • Wang-Lopez Q, et al. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? Crit Rev Oncol Hematol. 2015;95(1):88–104 Pathologic complete response (pCR) after PST has been suggested to be predictive of survival in breast cancer, although this fact remains a subject of controversy. This well-presented review addresses on the importance of an adequate definition of pCR and its significance in breast cancer outcomes.

    Article  PubMed  Google Scholar 

  14. Glück S, de Snoo F, Peeters J, Stork-Sloots L, Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013 Jun;139(3):759–67. doi:10.1007/s10549-013-2572-4.

    Article  PubMed  CAS  Google Scholar 

  15. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  16. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.

    Article  CAS  PubMed  Google Scholar 

  17. Swain SM, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;2017:646–53.

    Article  Google Scholar 

  18. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet Oncol. 2014;384:164–72.

    Article  Google Scholar 

  19. Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015;262(3):434–8.

    Article  PubMed  Google Scholar 

  20. • Chapman CH, Jagsi R. Postmastectomy radiotherapy after neoadjuvant chemotherapy: a review of the evidence. Oncology (Williston Park). 2015;29(9):657–66 This paper nicely reviews current evidence regarding PMRT use after PST and emphasizing the most controversial aspects and future directions.

    Google Scholar 

  21. Abdel-Wahab M, et al. The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: a phase II trial of neoadjuvant MVAC, surgery, and radiation. Int J Radiat Oncol Biol Phys. 1998;40(4):875–80.

    Article  CAS  PubMed  Google Scholar 

  22. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22(23):4691–9.

    Article  PubMed  Google Scholar 

  23. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62(2):351–7.

    Article  PubMed  Google Scholar 

  24. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SWC, Yu TK, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68(4):1004–9.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Sinn HP, et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd. 1994;54(10):552–8.

    Article  CAS  PubMed  Google Scholar 

  26. Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3(4):549–55.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.

    Article  PubMed  Google Scholar 

  28. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Boileau J-F, Poirier B, Basik M, Holloway CMB, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–64.

    Article  PubMed  Google Scholar 

  30. Boughey JC, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2017;263(4):802–7.

    Article  Google Scholar 

  31. Straver ME, Loo CE, Alderliesten T, Rutgers EJT, Peeters MTFDV. Marking the axilla with radioactive iodine seeds ( MARI procedure ) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer. Br J Surg. 2010;97:1226–31.

    Article  CAS  PubMed  Google Scholar 

  32. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. El H, et al. Refining the performance of sentinel lymph node biopsy post-neoadjuvant chemotherapy in patients with pathologically proven pre-treatment node-positive breast cancer : an update for clinical practice. Anticancer Res. 2016;1472:42–52.

    Google Scholar 

  34. Le Scodan R, et al. Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2012;82(1):e1–7.

    Article  PubMed  Google Scholar 

  35. Nagar H, Mittendorf EA, Strom EA, Perkins GH, Oh JL, Tereffe W, et al. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys. 2011;81(3):782–7.

    Article  PubMed  Google Scholar 

  36. Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Wright JL, Takita C, Reis IM, Zhao W, Saigal K, Wolfson A, et al. Predictors of locoregional outcome in patients receiving neoadjuvant therapy andpostmastectomy radiation. Cancer. 2013;119(1):16–25.

    Article  PubMed  Google Scholar 

  38. Diaz DA, Hurley J, Reis I, Takita C, Zhao W, Wright J. Locoregional outcomes in clinical stage IIB breast cancer after neoadjuvant therapy and mastectomy with or without radiation. Medicine (Baltimore). 2014;93(29):e230.

    Article  CAS  Google Scholar 

  39. Shim SJ, Park W, Huh SJ, Choi DH, Shin KH, Lee NK, et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2014;88(1):65–72.

    Article  PubMed  Google Scholar 

  40. Meattini I, Cecchini S, di Cataldo V, Saieva C, Francolini G, Scotti V, et al. Postmastectomy radiotherapy for locally advanced breast cancer receiving neoadjuvant chemotherapy. Biomed Res Int. 2014;2014:1–12.

    Article  Google Scholar 

  41. Arsenault D, Hurley J, Takita C, Reis IM, Zhao W, Rodgers S, et al. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy. Am J Clin Oncol. 2015;38(4):348–52.

    Article  CAS  PubMed  Google Scholar 

  42. Yang TJ, et al. The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation. Ann Surg Oncol. 2015;22(Suppl 3):S495–501.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Liu J, Mao K, Jiang S, Jiang W, Chen K, Kim BY, et al. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget. 2016;7(17):24848–59.

    Article  PubMed  Google Scholar 

  44. Rusthoven CG, Rabinovitch RA, Jones BL, Koshy M, Amini A, Yeh N, et al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(5):818–27.

    Article  CAS  Google Scholar 

  45. Huang L, Chen S, Yang WT, Shao Z. Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy. Oncotarget. 2017;8(24):39703–10.

    Article  PubMed  Google Scholar 

  46. • Gillon P, Touati N, Breton-Callu C, Slaets L, Cameron D, Bonnefoi H. Factors predictive of locoregional recurrence following neoadjuvant chemotherapyin patients with large operable or locally advanced breast cancer: an analysis of the EORTC 10994/BIG 1-00 study. Eur J Cancer. 2017;79:226–34 The results of this randomized, international and multicentre study confirm as factors directly related to the prognosis after PST both the unfavorable molecular subtype and the absence of pCR.

    Article  PubMed  Google Scholar 

  47. Rong QL, Wang SL, Tang Y, Jin J, Song YW, Wang WH, et al. The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy. Zhonghua Zhong Liu Za Zhi. 2017;39(6):445–52.

    CAS  PubMed  Google Scholar 

  48. • Ohri N, et al. Postmastectomy radiation in breast cancer patients with pathologically positive lymph nodes after neoadjuvant chemotherapy: usage rates and survival trends. Int J Radiat Oncol Biol Phys. 2017;99(3):549–59 Using data from NCDB including nearly 30,000 patients, the authors analyze the role and usage of PMRT after PST in patients ypN+.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Cao L, et al. Outcome of postmastectomy radiotherapy after primary systemic treatment in patients with clinical T1-2N1 breast cancer. Cancer Radiother. 2018;22(1):38–44.

    Article  CAS  PubMed  Google Scholar 

  50. Chen X, Xia F, Luo J, Ma J, Yang Z, Zhang L, et al. Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II-III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy. Onco Targets Ther. 2018;11:1973–80.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Beriwal S, Shinde A, Rajagopalan MS, Kannan N, Heron DE, Deutsch M. Recommendations for post-mastectomy radiation therapy after neo-adjuvant chemotherapy: an international survey of radiation oncologists. Breast J. 2013;19(6):683–4.

    Article  PubMed  Google Scholar 

  52. Fowble BL, Einck JP, Kim DN, McCloskey S, Mayadev J, Yashar C, et al. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):494–503.

    Article  PubMed  Google Scholar 

  53. Kantor O, Pesce C, Singh P, Miller M, Tseng J, Wang CH, et al. Post-mastectomy radiation therapy and overall survival after neoadjuvant chemotherapy. J Surg Oncol. 2017;115(6):668–76.

    Article  CAS  PubMed  Google Scholar 

  54. Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, et al. T3 disease at presentation or pathologic involvement of four or more lymph nodespredict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):138–45.

    Article  PubMed  Google Scholar 

  55. Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized. J Clin Oncol. 2004;22(21):4247–54.

    Article  PubMed  Google Scholar 

  56. Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61(5):1337–47.

    Article  PubMed  Google Scholar 

  57. NCT01872975, NSABP B51/Radiation Therapy Oncology Group (RTOG). Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery, 2019.

  58. NCT01901094, ALLIANCE A011202. Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy, 2019.

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University Hospital HM Sanchinarro, Madrid, Spain

    Ángel Montero & Raquel Ciérvide

  2. Department of Radiation Oncology, Institut Curie, 25, rue d’Ulm, 75248, Paris Cedex 05, France

    Philip Poortmans

  3. Paris Sciences et Lettres - PSL University, Paris, France

    Philip Poortmans

Authors
  1. Ángel Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raquel Ciérvide
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip Poortmans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip Poortmans.

Ethics declarations

Conflict of Interest

The authors declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Breast Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Montero, Á., Ciérvide, R. & Poortmans, P. When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy?. Curr Oncol Rep 21, 95 (2019). https://doi.org/10.1007/s11912-019-0850-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-019-0850-y

Keywords

Search

Navigation